Material Agreement (Form 8-K)

Item 1.01. Entry Into a Material Definitive Agreement

On December 6, 2025, Proteomedix AG, a Swiss Company ("Proteomedix"), a wholly-owned subsiairy of Onconetix, Inc. (the "Company"), entered into an amendment (the "Amendment") of the license agreement with Laboratory Corporation of America Holdings ("Labcorp") dated as of March 27, 2023, by and between the Company and Labcorp (the "Agreement"), pursuant to which Labcorp has the exclusive right to develop and commercialize Proclarix and other products developed by Labcorp using Proteomedix's intellectual property covered by the license in the United States (the "Licensed Products"). Pursuant to the Agreement, Labcorp is obligated to pay royalties on the net sales of any Licensed Products, as well as certain milestone payments.

The Amendment provides for a new validation study to be conducted by Labcorp for Proclarix, titled Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: A Prospective U.S.-Based Multi-Center Validation Study of Proclarix (the "PRIME Study"). Pursuant to the Amendment, Labcorp will not be required to pay any royalties or milestone payments in connection with its use of the risk calculator for purposes of the PRIME Study. The Company will compensate Labcorp with specified milestone-based payments for conducting the PRIME Study of up to $300,000 in the aggregate and will bear all associated costs and expenses. Mid-five figure milestone payments will be made as subjects are enrolled, commencing on the effective date of the PRIME Study and to be paid for every additional batch of subjects enrolled. If the final milestone tier is not reached, the Company must pay Labcorp a fixed amount per subject enrolled beyond the last milestone tier that was paid. All payments are due within thirty (30) days of each invoice.

Pursuant to the Amendment, Labcorp is also required to provide the Company with the results of each clinical study conducted by Labcorp upon completion; however, the Company may not use or disclose such results to any third party without Labcorp's prior consent.

The foregoing descriptions are qualified in their entirety by reference to the Amendment, which is filed herewith as Exhibit 10.1 2 hereto and is incorporated by reference herein.